Topics

Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform

05:05 EDT 10 Oct 2019 | EPM Magazine

A new initiative will see the Centre for Process Innovation (CPI) work with the University of Strathclyde, GSK and AstraZeneca to develop a platform to accelerate the development of oral solid dosage formulations.

Original Article: Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform

NEXT ARTICLE

More From BioPortfolio on "Manufacturing 'Grand Challenge' targets pharma to develop continuous formulation platform"

Quick Search

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

AstraZeneca
AstraZeneca is ranked 6th in the world, based on a pharmaceutical annual sales, which were valued at $32,800 million in 2009.  it is a global company, working in more than 100 countries, and employing 62,000 people, around a sixth of which are dedic...